WO2024031226A1 - Composition pharmaceutique et substance polymorphe d'inhibiteur de fgfr, et leur utilisation pharmaceutique - Google Patents

Composition pharmaceutique et substance polymorphe d'inhibiteur de fgfr, et leur utilisation pharmaceutique Download PDF

Info

Publication number
WO2024031226A1
WO2024031226A1 PCT/CN2022/110810 CN2022110810W WO2024031226A1 WO 2024031226 A1 WO2024031226 A1 WO 2024031226A1 CN 2022110810 W CN2022110810 W CN 2022110810W WO 2024031226 A1 WO2024031226 A1 WO 2024031226A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
crystal form
xrpd
pharmaceutical composition
Prior art date
Application number
PCT/CN2022/110810
Other languages
English (en)
Chinese (zh)
Inventor
高敏
宋嘉琦
张臻
喻红平
Original Assignee
无锡和誉生物医药科技有限公司
上海和誉生物医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 无锡和誉生物医药科技有限公司, 上海和誉生物医药科技有限公司 filed Critical 无锡和誉生物医药科技有限公司
Priority to PCT/CN2022/110810 priority Critical patent/WO2024031226A1/fr
Publication of WO2024031226A1 publication Critical patent/WO2024031226A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention belongs to the field of drug development, and specifically relates to pharmaceutical compositions and polymorphs of FGFR inhibitors and their pharmaceutical applications.
  • Protein kinases are a class of proteins (enzymes) that regulate various cellular functions. This is accomplished by phosphorylating specific amino acids on the protein substrate, causing conformational changes in the substrate protein. Conformational changes modulate the substrate activity or its ability to interact with other binding partners.
  • the enzymatic activity of a protein kinase refers to the rate at which the kinase adds phosphate groups to a substrate. This can be determined, for example, by measuring the amount of substrate converted to product as a function of time. Phosphorylation of substrate occurs in the active site of protein kinases.
  • Tyrosine kinases are a subgroup of protein kinases that catalyze the conversion of the terminal phosphate of adenosine triphosphate (ATP) to tyrosine residues on protein substrates. These kinases play an important role in the propagation of growth factor signaling that leads to cell proliferation, differentiation, and migration.
  • ATP adenosine triphosphate
  • Fibroblast growth factor is considered an important mediator of many physiological processes such as morphogenesis during development and vasculogenesis.
  • FGF Fibroblast growth factor
  • the fibroblast growth factor receptor (FGFR) family includes four members, FGFR1, FGFR2, FGFR3, and FGFR4, each of which consists of an extracellular ligand-binding domain, a single transmembrane domain, and an intracellular cytoplasmic protein tyrosine kinase domain.
  • FGFR dimerization and transphosphorylation occur, which results in receptor activation.
  • Activation of the receptor is sufficient to restore and activate specific downstream signaling partners involved in various processes such as the regulation of cell growth, cell metabolism and cell survival (reviewed in Eswarakumar, V.P. et al., Cytokine & Growth Factor Reviews 2005, 16 , pp. 139-149).
  • FGF and FGFR may cause and/or promote tumor formation.
  • FGF signaling directly in human cancer Increased expression of various FGFs has been reported in a diverse range of tumor types such as bladder, renal cell and prostate (among others) tumors. FGF has also been described as a potent angiogenic factor. It has also been reported that FGFR is expressed in endothelial cells. Activating mutations of various FGFRs are associated with bladder cancer and multiple myeloma (among others), and there is evidence that the receptor is also expressed in prostate and bladder cancer, among others (reviewed in Grose, R. et al., Cytokine & Growth Factor Reviews 2005, 16 , pp. 179-186 and Kwabi-Addo, B.
  • AstraZeneca (Sweden) Ltd. ASTRAZENECA AB
  • AstraZeneca (Sweden) Ltd. ASTRAZENECA AB
  • the most representative compound is the compound of Example 154. Chemistry The structure is as follows:
  • the Chinese name is: N-(3-(3,5-dimethoxyphenylethyl)-1H-pyrazol-5-yl)-4-((3S,5R)-3,5-dimethylpiper Azin-1-yl)benzamide (AZD4547), referred to as the compound of formula (I) herein, can be used as an FGFR activity modulator or inhibitor to meet the current domestic and foreign requirements for the treatment of proliferative and hyperproliferative diseases/diseases.
  • cancer including but not limited to liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma.
  • liver cancer prostate cancer
  • pancreatic cancer pancreatic cancer
  • esophageal cancer gastric cancer
  • lung cancer breast cancer
  • ovarian cancer colon cancer
  • skin cancer glioblastoma or rhabdomyosarcoma
  • the purpose of the present invention is to provide pharmaceutical compositions and polymorphs of FGFR inhibitors to solve the problem of drug accessibility and meet the needs of AZD4547 clinical research and drug marketing.
  • the inventors optimized the types and proportions of pharmaceutical carriers such as lubricants, disintegrants, and fillers by using appropriate binders, and at the same time conducted in-depth research on the aggregation state of the compound of formula (I).
  • pharmaceutical carriers such as lubricants, disintegrants, and fillers
  • binders such as binders
  • crystal form screening experiments screen out crystal forms of compounds of formula (I) that can be used in formulation development.
  • Combining the results of preparation research and crystal form research we developed a pharmaceutical composition that is highly compressible and suitable for industrial production.
  • We obtained a pharmaceutical preparation that meets clinical requirements in terms of stability, solubility and other physical and chemical properties, and can meet the clinical research of AZD4547. and the need for drug launches.
  • the first aspect of the present invention provides a pharmaceutical composition, which contains the crystal form of a compound of formula (I) as follows and one or more pharmaceutically acceptable carriers.
  • the pharmaceutically acceptable carrier is a lubricant, a disintegrating agent, or a disintegrating agent.
  • the pharmaceutical composition also includes hydroxypropyl cellulose as a binder, the binder is hydroxypropyl cellulose of LF and/or JF grade specifications, or the above Specifications mixed with other specifications of hydroxypropylcellulose,
  • the pharmaceutical composition contains 0.1%-50% W/W crystalline form of the compound of formula (I) relative to the total weight of the composition.
  • the pharmaceutical composition contains 1.0%-30% W/W crystalline form of the compound of formula (I) relative to the total weight of the composition.
  • the pharmaceutical composition contains 10.0%-30% W/W crystalline form of the compound of formula (I) relative to the total weight of the composition.
  • the pharmaceutical composition contains 0.5%-20.0% W/W LF and/or JF grade specifications of hydroxypropyl cellulose relative to the total weight of the composition, or the above specifications are combined with other specifications of hydroxypropyl cellulose. Mixture of vegetarian ingredients.
  • hydroxypropyl cellulose refers to EF, GF, MF or HXF grade hydroxypropyl cellulose.
  • the pharmaceutical composition contains 1.0%-10.0% W/W LF and/or JF grade hydroxypropyl cellulose relative to the total weight of the composition, or the above specifications are combined with other specifications of hydroxypropyl cellulose.
  • a mixture of cellulose 1.0%-10.0% W/W LF and/or JF grade hydroxypropyl cellulose relative to the total weight of the composition, or the above specifications are combined with other specifications of hydroxypropyl cellulose. A mixture of cellulose.
  • the pharmaceutical composition contains 2.0%-8.0% W/W LF and/or JF grade hydroxypropyl cellulose relative to the total weight of the composition, or the above specifications are combined with other specifications of hydroxypropyl cellulose.
  • the pharmaceutical composition contains hydroxypropyl cellulose in LF and/or JF grade specifications.
  • the pharmaceutical composition contains LF and/or JF grade hydroxypropylcellulose in an aqueous solution.
  • the pharmaceutical composition contains an aqueous solution of hydroxypropylcellulose of LF and/or JF grade specifications at a concentration of 5% to 25% W/V relative to the total weight of the composition.
  • the pharmaceutical composition contains the hydroxypropylcellulose aqueous solution of LF and/or JF grade specifications at a concentration of 8% to 15% W/V relative to the total weight of the composition.
  • the pharmaceutical composition further contains one or more foaming agents, which are inorganic salts or organic carbonates.
  • the inorganic salts are selected from the group consisting of sodium carbonate, potassium carbonate, and magnesium carbonate. , calcium carbonate, aluminum carbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium hydroxide; the organic acid salt is selected from sodium diglycinate carbonate, dimethyl Carbonate and ethylene carbonate.
  • the foaming agent is selected from the group consisting of sodium carbonate, potassium carbonate, magnesium carbonate, calcium carbonate, aluminum carbonate, sodium bicarbonate, potassium bicarbonate and calcium bicarbonate.
  • the pharmaceutical composition contains 0.5%-50.0% W/W foaming agent relative to the total weight of the composition.
  • the pharmaceutical composition contains 2.0%-40.0% W/W foaming agent relative to the total weight of the composition.
  • the pharmaceutical composition contains 10.0%-30.0% W/W foaming agent relative to the total weight of the composition.
  • the lubricant is one of glyceryl behenate, magnesium stearate, sodium stearyl fumarate, colloidal silicon dioxide, talc, hydrogenated vegetable oil and triglyceride. kind or variety.
  • the pharmaceutical composition contains 0.1%-30.0% W/W lubricant relative to the total weight of the composition.
  • the pharmaceutical composition contains 1.0%-25.0% W/W lubricant relative to the total weight of the composition.
  • the pharmaceutical composition contains 3.0%-18.0% W/W lubricant relative to the total weight of the composition.
  • the disintegrant is one or more of sodium starch glycolate, sodium starch glycolate, cross-linked polyvinylpyrrolidone and croscarmellose sodium.
  • the pharmaceutical composition contains 0.5%-20.0% W/W disintegrant relative to the total weight of the composition.
  • the pharmaceutical composition contains 1.0%-10.0% W/W disintegrant relative to the total weight of the composition.
  • the pharmaceutical composition contains 2.0%-8.0% W/W disintegrant relative to the total weight of the composition.
  • the filler is one or more of mannitol, lactose, microcrystalline cellulose, silicified microcrystalline cellulose, dicalcium phosphate, anhydrous calcium hydrogen phosphate and lactose monohydrate.
  • the pharmaceutical composition contains 1.0%-90.0% W/W filler relative to the total weight of the composition.
  • the pharmaceutical composition contains 5.0%-60.0% W/W filler relative to the total weight of the composition.
  • the pharmaceutical composition contains 10.0%-45.0% W/W filler relative to the total weight of the composition.
  • the pharmaceutical composition includes the crystal form of the compound of formula (I), LF grade hydroxypropyl cellulose and a lubricant, with a W/W mass ratio of (10.0-30.0): (2.0-8.0 ): (3.0-10.0), the lubricant is one or more of glyceryl behenate, magnesium stearate and silicon dioxide.
  • the pharmaceutical composition further contains sodium carbonate and/or magnesium carbonate as a foaming agent, the content of which is 2.0%-40.0% W/W relative to the total weight of the composition.
  • the pharmaceutical composition further contains sodium carbonate and/or magnesium carbonate as a foaming agent, the content of which is 10.0%-30.0% W/W relative to the total weight of the composition.
  • the pharmaceutical composition further contains sodium starch glycolate as a disintegrant, the content of which is 2.0%-8.0% W/W relative to the total weight of the composition.
  • the pharmaceutical composition further contains microcrystalline cellulose and/or mannitol as fillers, the content of which is 5.0%-45.0% W/W relative to the total weight of the composition.
  • the pharmaceutical composition further contains microcrystalline cellulose and/or mannitol as fillers, the content of which is 10.0%-35.0% W/W relative to the total weight of the composition.
  • the pharmaceutical composition further contains microcrystalline cellulose and/or mannitol as fillers, the content of which is 15.0%-25.0% W/W relative to the total weight of the composition.
  • the pharmaceutical composition further includes one or more coating powders as coating materials.
  • the coating powder contained in the pharmaceutical composition is gastric-soluble film coating premix Opadry.
  • the pharmaceutical composition is a tablet.
  • the unit dosage form of the tablet contains 1 mg to 500 mg of the crystalline form of the compound of formula (I).
  • the unit dosage form of the tablet contains 1 mg to 200 mg of the crystalline form of the compound of formula (I).
  • the unit dosage form of the tablet contains 1 mg, 5 mg, 20 mg, 80 mg or 200 mg of the crystalline form of the compound of formula (I).
  • the crystal form of the compound of formula (I) is anhydrous, hydrate or solvate of the compound of formula (I).
  • the solvate of the compound of formula (I) is 2-methyltetrahydrofuran solvate, isopropanol solvate and isopropanol-aqueous solvate.
  • the pharmaceutical composition contains anhydrous crystal form I of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystal form I of the compound of formula (I) includes a Peaks at diffraction angles (2 ⁇ ) of 22.86 ⁇ 0.2°, 7.81 ⁇ 0.2°, 29.89 ⁇ 0.2°, 21.35 ⁇ 0.2°, 16.16 ⁇ 0.2°, 20.73 ⁇ 0.2° and 27.04 ⁇ 0.2°.
  • the pharmaceutical composition comprises the anhydrous crystalline form I of the compound of formula (I).
  • the X-ray powder diffraction pattern (XRPD) of the anhydrous crystalline form I of the compound of formula (I) includes a position at 22.86 ⁇ 0.2°, 7.81 ⁇ 0.2°, 29.89 ⁇ 0.2°, 21.35 ⁇ 0.2°, 16.16 ⁇ 0.2°, 20.73 ⁇ 0.2°, 27.04 ⁇ 0.2°, 16.64 ⁇ 0.2°, 24.89 ⁇ 0.2°, 25.09 ⁇ 0.2°, 23.51 Peaks at diffraction angles (2 ⁇ ) of ⁇ 0.2°, 13.37 ⁇ 0.2°, 21.84 ⁇ 0.2°, 12.71 ⁇ 0.2° and 17.85 ⁇ 0.2°.
  • the pharmaceutical composition contains the anhydrous crystalline form I of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystalline form I of the compound of formula (I) includes a position at 22.86 ⁇ 0.2°, 7.81 ⁇ 0.2°, 29.89 ⁇ 0.2°, 21.35 ⁇ 0.2°, 16.16 ⁇ 0.2°, 20.73 ⁇ 0.2°, 27.04 ⁇ 0.2°, 16.64 ⁇ 0.2°, 24.89 ⁇ 0.2°, 25.09 ⁇ 0.2°, 23.51 ⁇ 0.2°, 13.37 ⁇ 0.2°, 21.84 ⁇ 0.2°, 12.71 ⁇ 0.2°, 17.85 ⁇ 0.2°, 12.86 ⁇ 0.2°, 24.30 ⁇ 0.2°, 26.53 ⁇ 0.2°, 23.74 ⁇ 0.2°, 18.24 ⁇ 0.2°, 28.75 Peaks at diffraction angles (2 ⁇ ) of ⁇ 0.2°, 19.65 ⁇ 0.2°, 11.23 ⁇ 0.2°, 32.66 ⁇ 0.2° and 18.91 ⁇ 0.2°.
  • XRPD X-ray powder diffraction pattern
  • the pharmaceutical composition contains the anhydrous crystalline form II of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystalline form II of the compound of formula (I) includes a Peaks at diffraction angles (2 ⁇ ) of 22.88 ⁇ 0.2°, 7.82 ⁇ 0.2°, 29.92 ⁇ 0.2°, 23.51 ⁇ 0.2°, 21.37 ⁇ 0.2°, 27.06 ⁇ 0.2° and 24.90 ⁇ 0.2°.
  • XRPD X-ray powder diffraction pattern
  • the pharmaceutical composition contains the anhydrous crystalline form II of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystalline form II of the compound of formula (I) includes a 22.88 ⁇ 0.2°, 7.82 ⁇ 0.2°, 29.92 ⁇ 0.2°, 23.51 ⁇ 0.2°, 21.37 ⁇ 0.2°, 27.06 ⁇ 0.2°, 24.90 ⁇ 0.2°, 16.65 ⁇ 0.2°, 20.76 ⁇ 0.2°, 25.11 ⁇ 0.2°, Peaks at diffraction angles (2 ⁇ ) of 16.18 ⁇ 0.2°, 13.38 ⁇ 0.2°, 21.86 ⁇ 0.2°, 32.58 ⁇ 0.2° and 12.72 ⁇ 0.2°.
  • XRPD X-ray powder diffraction pattern
  • the pharmaceutical composition contains the anhydrous crystalline form II of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystalline form II of the compound of formula (I) includes a position at 22.88 ⁇ 0.2°, 7.82 ⁇ 0.2°, 29.92 ⁇ 0.2°, 23.51 ⁇ 0.2°, 21.37 ⁇ 0.2°, 27.06 ⁇ 0.2°, 24.90 ⁇ 0.2°, 16.65 ⁇ 0.2°, 20.76 ⁇ 0.2°, 25.11 ⁇ 0.2°, 16.18 ⁇ 0.2°, 13.38 ⁇ 0.2°, 21.86 ⁇ 0.2°, 32.58 ⁇ 0.2°, 12.72 ⁇ 0.2°, 24.31 ⁇ 0.2°, 15.05 ⁇ 0.2°, 28.77 ⁇ 0.2°, 26.55 ⁇ 0.2°, 12.87 ⁇ 0.2°, 22.56 Peaks at diffraction angles (2 ⁇ ) of ⁇ 0.2°, 17.85 ⁇ 0.2°, 23.76 ⁇ 0.2°, 18.26 ⁇ 0.2° and 31.11 ⁇ 0.2°.
  • the pharmaceutical composition contains the anhydrous crystalline form III of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystalline form III of the compound of formula (I) includes the Peaks at diffraction angles (2 ⁇ ) of 5.85 ⁇ 0.2°, 21.34 ⁇ 0.2°, 14.96 ⁇ 0.2°, 20.57 ⁇ 0.2°, 19.78 ⁇ 0.2°, 24.12 ⁇ 0.2° and 18.71 ⁇ 0.2°.
  • XRPD X-ray powder diffraction pattern
  • the pharmaceutical composition contains the anhydrous crystalline form III of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystalline form III of the compound of formula (I) includes the 5.85 ⁇ 0.2°, 21.34 ⁇ 0.2°, 14.96 ⁇ 0.2°, 20.57 ⁇ 0.2°, 19.78 ⁇ 0.2°, 24.12 ⁇ 0.2°, 18.71 ⁇ 0.2°, 25.13 ⁇ 0.2°, 13.72 ⁇ 0.2°, 24.65 ⁇ 0.2°, Peaks at diffraction angles (2 ⁇ ) of 22.76 ⁇ 0.2°, 26.75 ⁇ 0.2°, 14.61 ⁇ 0.2°, 10.81 ⁇ 0.2° and 16.81 ⁇ 0.2°.
  • XRPD X-ray powder diffraction pattern
  • the pharmaceutical composition contains the anhydrous crystalline form III of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystalline form III of the compound of formula (I) includes a position at 5.85 ⁇ 0.2°, 21.34 ⁇ 0.2°, 14.96 ⁇ 0.2°, 20.57 ⁇ 0.2°, 19.78 ⁇ 0.2°, 24.12 ⁇ 0.2°, 18.71 ⁇ 0.2°, 25.13 ⁇ 0.2°, 13.72 ⁇ 0.2°, 24.65 ⁇ 0.2°, 22.76 ⁇ 0.2°, 26.75 ⁇ 0.2°, 14.61 ⁇ 0.2°, 10.81 ⁇ 0.2°, 16.81 ⁇ 0.2°, 21.14 ⁇ 0.2°, 22.54 ⁇ 0.2°, 9.74 ⁇ 0.2°, 21.79 ⁇ 0.2°, 25.74 ⁇ 0.2°, 17.71 Peaks at diffraction angles (2 ⁇ ) of ⁇ 0.2°, 19.33 ⁇ 0.2°, 30.36 ⁇ 0.2°, 13.39 ⁇ 0.2° and 14.07 ⁇ 0.2°.
  • the pharmaceutical composition contains the hydrate crystal form IV of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form IV of the compound of formula (I) includes a position located at 13.34 ⁇ Peaks at diffraction angles (2 ⁇ ) of 0.2°, 17.41 ⁇ 0.2°, 21.78 ⁇ 0.2°, 20.02 ⁇ 0.2°, 14.85 ⁇ 0.2° and 16.53 ⁇ 0.2°.
  • XRPD X-ray powder diffraction pattern
  • the pharmaceutical composition contains the hydrate crystal form IV of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form IV of the compound of formula (I) includes a position located at 13.34 ⁇ 0.2°, 17.41 ⁇ 0.2°, 21.78 ⁇ 0.2°, 20.02 ⁇ 0.2°, 14.85 ⁇ 0.2°, 16.53 ⁇ 0.2°, 19.35 ⁇ 0.2°, 18.64 ⁇ 0.2°, 11.19 ⁇ 0.2°, 5.98 ⁇ 0.2° and 22.67 ⁇ Peak at diffraction angle (2 ⁇ ) of 0.2°.
  • XRPD X-ray powder diffraction pattern
  • the pharmaceutical composition contains the hydrate crystalline form IV of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the hydrate crystalline form IV of the compound of formula (I) includes a position at 13.34 ⁇ 0.2 °, 17.41 ⁇ 0.2°, 21.78 ⁇ 0.2°, 20.02 ⁇ 0.2°, 14.85 ⁇ 0.2°, 16.53 ⁇ 0.2°, 19.35 ⁇ 0.2°, 18.64 ⁇ 0.2°, 11.19 ⁇ 0.2°, 5.98 ⁇ 0.2°, 22.67 ⁇ 0.2 °, 20.62 ⁇ 0.2°, 26.72 ⁇ 0.2°, 14.08 ⁇ 0.2°, 23.82 ⁇ 0.2° and 25.37 ⁇ 0.2° peaks at diffraction angles (2 ⁇ ).
  • XRPD X-ray powder diffraction pattern
  • the pharmaceutical composition contains the hydrate crystal form VIII of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form VIII of the compound of formula (I) includes a position at 23.05 ⁇ Peaks at diffraction angles (2 ⁇ ) of 0.2°, 8.73 ⁇ 0.2°, 21.41 ⁇ 0.2°, 15.95 ⁇ 0.2°, 23.50 ⁇ 0.2°, 15.50 ⁇ 0.2° and 25.14 ⁇ 0.2°.
  • the pharmaceutical composition contains the hydrate crystal form VIII of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form VIII of the compound of formula (I) includes a position at 23.05 ⁇ 0.2°, 8.73 ⁇ 0.2°, 21.41 ⁇ 0.2°, 15.95 ⁇ 0.2°, 23.50 ⁇ 0.2°, 15.50 ⁇ 0.2°, 25.14 ⁇ 0.2°, 27.00 ⁇ 0.2°, 31.15 ⁇ 0.2°, 27.70 ⁇ 0.2°, 16.81 ⁇ Peaks at diffraction angles (2 ⁇ ) of 0.2°, 19.70 ⁇ 0.2°, 13.22 ⁇ 0.2°, 24.34 ⁇ 0.2° and 19.32 ⁇ 0.2°.
  • XRPD X-ray powder diffraction pattern
  • the pharmaceutical composition contains the hydrate crystal form VIII of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form VIII of the compound of formula (I) includes a position at 23.05 ⁇ 0.2 °, 8.73 ⁇ 0.2°, 21.41 ⁇ 0.2°, 15.95 ⁇ 0.2°, 23.50 ⁇ 0.2°, 15.50 ⁇ 0.2°, 25.14 ⁇ 0.2°, 27.00 ⁇ 0.2°, 31.15 ⁇ 0.2°, 27.70 ⁇ 0.2°, 16.81 ⁇ 0.2 °, 19.70 ⁇ 0.2°, 13.22 ⁇ 0.2°, 24.34 ⁇ 0.2°, 19.32 ⁇ 0.2°, 20.44 ⁇ 0.2°, 35.08 ⁇ 0.2°, 29.93 ⁇ 0.2°, 27.32 ⁇ 0.2°, 13.54 ⁇ 0.2°, 18.99 ⁇ 0.2 °, 12.89 ⁇ 0.2°, 17.49 ⁇ 0.2°, 30.49 ⁇ 0.2° and 18.59 ⁇ 0.2° peaks at diffraction angles (2 ⁇ ).
  • the pharmaceutical composition contains a crystalline form of a hydrate of the compound of formula (I), and the hydrate of the compound of formula (I) contains 0.5-3.0 water molecules per molecule.
  • the pharmaceutical composition contains a crystalline form of a hydrate of the compound of formula (I), and the hydrate of the compound of formula (I) contains 0.9-1.8 water molecules per molecule.
  • the pharmaceutical composition contains the compound of formula (I) 2-methyltetrahydrofuran solvate crystal form VI, and the X of the compound of formula (I) 2-methyltetrahydrofuran solvate crystal form VI - Ray powder diffraction pattern (XRPD) includes diffraction angles (2 ⁇ ) at 22.44 ⁇ 0.2°, 5.63 ⁇ 0.2°, 16.81 ⁇ 0.2°, 20.43 ⁇ 0.2°, 21.57 ⁇ 0.2°, 16.15 ⁇ 0.2° and 22.71 ⁇ 0.2° The peak at.
  • the pharmaceutical composition contains the compound of formula (I) 2-methyltetrahydrofuran solvate crystal form VI, and the X of the compound of formula (I) 2-methyltetrahydrofuran solvate crystal form VI -Ray powder diffraction pattern (XRPD) includes locations at 22.44 ⁇ 0.2°, 5.63 ⁇ 0.2°, 16.81 ⁇ 0.2°, 20.43 ⁇ 0.2°, 21.57 ⁇ 0.2°, 16.15 ⁇ 0.2°, 22.71 ⁇ 0.2°, 6.36 ⁇ 0.2°, Peaks at diffraction angles (2 ⁇ ) of 12.60 ⁇ 0.2°, 25.95 ⁇ 0.2°, 24.92 ⁇ 0.2°, 13.69 ⁇ 0.2°, 19.65 ⁇ 0.2°, 15.13 ⁇ 0.2° and 12.11 ⁇ 0.2°.
  • the pharmaceutical composition contains the compound of formula (I) 2-methyltetrahydrofuran solvate crystal form VI, and the X- of the compound of formula (I) 2-methyltetrahydrofuran solvate crystal form VI
  • the XRPD patterns include 22.44 ⁇ 0.2°, 5.63 ⁇ 0.2°, 16.81 ⁇ 0.2°, 20.43 ⁇ 0.2°, 21.57 ⁇ 0.2°, 16.15 ⁇ 0.2°, 22.71 ⁇ 0.2°, 6.36 ⁇ 0.2°, 12.60 ⁇ 0.2°, 25.95 ⁇ 0.2°, 24.92 ⁇ 0.2°, 13.69 ⁇ 0.2°, 19.65 ⁇ 0.2°, 15.13 ⁇ 0.2°, 12.11 ⁇ 0.2°, 24.25 ⁇ 0.2°, 11.16 ⁇ 0.2°, 31.57 ⁇ 0.2°, 14.55 Peaks at diffraction angles (2 ⁇ ) of ⁇ 0.2°, 27.00 ⁇ 0.2°, 17.90 ⁇ 0.2°, 21.12 ⁇ 0.2°, 11.27 ⁇ 0.2°, 23.18 ⁇ 0.2° and 14.12 ⁇ 0.2°.
  • the pharmaceutical composition contains the crystal form of the 2-methyltetrahydrofuran solvate of the compound of formula (I), and each molecule of the 2-methyltetrahydrofuran solvate of the compound of formula (I) contains 0.5 -3.0 molecules of 2-methyltetrahydrofuran.
  • the pharmaceutical composition contains the crystal form of the 2-methyltetrahydrofuran solvate of the compound of formula (I), and each molecule of the 2-methyltetrahydrofuran solvate of the compound of formula (I) contains 1.0 2-methyltetrahydrofuran molecules.
  • the pharmaceutical composition contains the isopropanol solvate crystal form V of the compound of formula (I), and the X-ray powder diffraction of the isopropyl alcohol solvate crystal form V of the compound of formula (I)
  • the pattern (XRPD) includes peaks at diffraction angles (2 ⁇ ) of 5.28 ⁇ 0.2°, 10.52 ⁇ 0.2°, 21.29 ⁇ 0.2°, 5.66 ⁇ 0.2°, 13.52 ⁇ 0.2°, 22.44 ⁇ 0.2° and 19.35 ⁇ 0.2°.
  • the pharmaceutical composition contains the isopropanol solvate crystal form V of the compound of formula (I), and the X-ray powder diffraction of the isopropyl alcohol solvate crystal form V of the compound of formula (I)
  • the graph (XRPD) includes locations at 5.28 ⁇ 0.2°, 10.52 ⁇ 0.2°, 21.29 ⁇ 0.2°, 5.66 ⁇ 0.2°, 13.52 ⁇ 0.2°, 22.44 ⁇ 0.2°, 19.35 ⁇ 0.2°, 18.48 ⁇ 0.2°, 16.77 ⁇ 0.2° , 24.68 ⁇ 0.2°, 19.97 ⁇ 0.2°, 25.67 ⁇ 0.2°, 15.13 ⁇ 0.2°, 17.82 ⁇ 0.2° and 20.96 ⁇ 0.2° peaks at diffraction angles (2 ⁇ ).
  • the pharmaceutical composition contains the isopropyl alcohol solvate crystal form V of the compound of formula (I), and the X-ray powder diffraction pattern of the isopropyl alcohol solvate crystal form V of the compound of formula (I) (XRPD) includes locations at 5.28 ⁇ 0.2°, 10.52 ⁇ 0.2°, 21.29 ⁇ 0.2°, 5.66 ⁇ 0.2°, 13.52 ⁇ 0.2°, 22.44 ⁇ 0.2°, 19.35 ⁇ 0.2°, 18.48 ⁇ 0.2°, 16.77 ⁇ 0.2°, 24.68 ⁇ 0.2°, 19.97 ⁇ 0.2°, 25.67 ⁇ 0.2°, 15.13 ⁇ 0.2°, 17.82 ⁇ 0.2°, 20.96 ⁇ 0.2°, 14.86 ⁇ 0.2°, 12.48 ⁇ 0.2°, 11.94 ⁇ 0.2°, 14.24 ⁇ 0.2°, Peaks at diffraction angles (2 ⁇ ) of 23.87 ⁇ 0.2°, 23.25 ⁇ 0.2°, 29.51 ⁇ 0.2° and 27.70 ⁇ 0.2°.
  • XRPD X-ray powder diffraction pattern of the isopropyl alcohol solvate crystal
  • the pharmaceutical composition contains the isopropanol solvate crystal form of the compound of formula (I), and the isopropyl alcohol solvate of the compound of formula (I) contains 1.0-5.0 isopropanol in each molecule. Propanol molecule.
  • the pharmaceutical composition contains the isopropyl alcohol solvate crystal form of the compound of formula (I), and the isopropyl alcohol solvate of the compound of formula (I) contains 4.2 isopropyl alcohols per molecule. molecular.
  • the pharmaceutical composition contains the isopropyl alcohol-aqueous solvate crystal form VII of the compound of formula (I), and the isopropyl alcohol-aqua solvate crystal form VII of the compound of formula (I)
  • the X-ray powder diffraction pattern (XRPD) includes diffraction angles located at 23.77 ⁇ 0.2°, 24.36 ⁇ 0.2°, 18.56 ⁇ 0.2°, 5.94 ⁇ 0.2°, 22.59 ⁇ 0.2°, 20.30 ⁇ 0.2° and 17.79 ⁇ 0.2° ( 2 ⁇ ) peak.
  • the pharmaceutical composition contains the isopropyl alcohol-aqueous solvate crystal form VII of the compound of formula (I), and the isopropyl alcohol-aqua solvate crystal form VII of the compound of formula (I)
  • the X-ray powder diffraction pattern includes locations at 23.77 ⁇ 0.2°, 24.36 ⁇ 0.2°, 18.56 ⁇ 0.2°, 5.94 ⁇ 0.2°, 22.59 ⁇ 0.2°, 20.30 ⁇ 0.2°, 17.79 ⁇ 0.2°, 10.33 ⁇ 0.2 °, 12.10 ⁇ 0.2°, 22.26 ⁇ 0.2°, 19.48 ⁇ 0.2°, 21.73 ⁇ 0.2°, 5.29 ⁇ 0.2°, 25.80 ⁇ 0.2° and 16.45 ⁇ 0.2° at diffraction angles (2 ⁇ ).
  • the pharmaceutical composition contains the isopropyl alcohol-aqueous solvate crystal form VII of the compound of formula (I), and the isopropyl alcohol-aqueous solvate crystal form VII of the compound of formula (I) is X-ray powder diffraction patterns (XRPD) include locations at 23.77 ⁇ 0.2°, 24.36 ⁇ 0.2°, 18.56 ⁇ 0.2°, 5.94 ⁇ 0.2°, 22.59 ⁇ 0.2°, 20.30 ⁇ 0.2°, 17.79 ⁇ 0.2°, 10.33 ⁇ 0.2° , 12.10 ⁇ 0.2°, 22.26 ⁇ 0.2°, 19.48 ⁇ 0.2°, 21.73 ⁇ 0.2°, 5.29 ⁇ 0.2°, 25.80 ⁇ 0.2°, 16.45 ⁇ 0.2°, 21.94 ⁇ 0.2°, 28.33 ⁇ 0.2°, 25.04 ⁇ 0.2° , 11.89 ⁇ 0.2°, 17.26 ⁇ 0.2°, 28.85 ⁇ 0.2°, 16.79 ⁇ 0.2°, 23.34 ⁇ 0.2°, 30.31 ⁇ 0.2° and 14.26 ⁇ 0.2° peaks at diffraction angles (2 ⁇ ).
  • the pharmaceutical composition contains the isopropanol-aqueous solvate crystal form of the compound of formula (I), and each molecule of the isopropyl alcohol-aqueous solvate of the compound of formula (I) contains Contains 0.5-3 isopropyl alcohol molecules and 0.5-3.0 water molecules.
  • the pharmaceutical composition contains the isopropanol-aqueous solvate crystal form of the compound of formula (I), and each molecule of the isopropyl alcohol-aqueous solvate of the compound of formula (I) contains Contains 2.0 molecules of isopropyl alcohol and contains 1.5 molecules of water.
  • a second aspect of the present invention provides a preparation method of the aforementioned pharmaceutical composition, comprising the following steps:
  • Step A Mix the crystal form of the compound of formula (I) and/or one or more pharmaceutically acceptable carriers to obtain a premixed material;
  • Step B Add the binder hydroxypropyl cellulose to the above premixed materials to form mixed particles;
  • step C add lubricant and/or disintegrant to the above mixed particles to form final mixed particles;
  • step D compress the final mixed granules prepared in the above step C to form tablets;
  • the pharmaceutically acceptable carrier is one or more of lubricants, disintegrants and fillers.
  • a foaming agent is added during premixing in step A of the preparation method.
  • the preparation method can mix the compound of formula (I), the binder hydroxypropyl cellulose, the foaming agent and one or more pharmaceutically acceptable carriers to obtain a premixed material.
  • step B of the preparation method is performed after mixing to form wet granules and then drying and/or dry granulation.
  • step A and/or step B of the preparation method is passed through a 30-100 mesh sieve.
  • a third aspect of the present invention provides the crystalline form of anhydride, hydrate or solvate of the compound of formula (I):
  • the solvate of the compound of formula (I) is 2-methyltetrahydrofuran solvate, isopropyl alcohol solvate and isopropyl alcohol-water heterosolvate.
  • the crystal form is the anhydrous crystal form I of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystal form I of the compound of formula (I) includes a position at 22.86 ⁇ Peaks at diffraction angles (2 ⁇ ) of 0.2°, 7.81 ⁇ 0.2°, 29.89 ⁇ 0.2°, 21.35 ⁇ 0.2°, 16.16 ⁇ 0.2°, 20.73 ⁇ 0.2° and 27.04 ⁇ 0.2°.
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern (XRPD) of the anhydrous crystal form I of the compound of formula (I) includes positions at 22.86 ⁇ 0.2°, 7.81 ⁇ 0.2°, 29.89 ⁇ 0.2°, and 21.35 ⁇ 0.2 °, 16.16 ⁇ 0.2°, 20.73 ⁇ 0.2°, 27.04 ⁇ 0.2°, 16.64 ⁇ 0.2°, 24.89 ⁇ 0.2°, 25.09 ⁇ 0.2°, 23.51 ⁇ 0.2°, 13.37 ⁇ 0.2°, 21.84 ⁇ 0.2°, 12.71 ⁇ 0.2 ° and peaks at diffraction angles (2 ⁇ ) of 17.85 ⁇ 0.2°.
  • the X-ray powder diffraction pattern (XRPD) of the anhydrous crystal form I of the compound of formula (I) includes positions at 22.86 ⁇ 0.2°, 7.81 ⁇ 0.2°, 29.89 ⁇ 0.2°, and 21.35 ⁇ 0.2°.
  • the crystal form is the anhydrous crystal form II of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystal form II of the compound of formula (I) includes a position at 22.88 ⁇ 0.2 °, 7.82 ⁇ 0.2°, 29.92 ⁇ 0.2°, 23.51 ⁇ 0.2°, 21.37 ⁇ 0.2°, 27.06 ⁇ 0.2° and 24.90 ⁇ 0.2° peaks at diffraction angles (2 ⁇ ).
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern (XRPD) of the anhydrous crystal form II of the compound of formula (I) includes positions at 22.88 ⁇ 0.2°, 7.82 ⁇ 0.2°, 29.92 ⁇ 0.2°, and 23.51 ⁇ 0.2°. , 21.37 ⁇ 0.2°, 27.06 ⁇ 0.2°, 24.90 ⁇ 0.2°, 16.65 ⁇ 0.2°, 20.76 ⁇ 0.2°, 25.11 ⁇ 0.2°, 16.18 ⁇ 0.2°, 13.38 ⁇ 0.2°, 21.86 ⁇ 0.2°, 32.58 ⁇ 0.2° and a peak at a diffraction angle (2 ⁇ ) of 12.72 ⁇ 0.2°.
  • the X-ray powder diffraction pattern (XRPD) of the anhydrous crystal form II of the compound of formula (I) includes positions at 22.88 ⁇ 0.2°, 7.82 ⁇ 0.2°, 29.92 ⁇ 0.2°, and 23.51 ⁇ 0.2°.
  • the crystal form is the anhydrous crystal form III of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the anhydrous crystal form III of the compound of formula (I) includes a position at 5.85 ⁇ 0.2 °, 21.34 ⁇ 0.2°, 14.96 ⁇ 0.2°, 20.57 ⁇ 0.2°, 19.78 ⁇ 0.2°, 24.12 ⁇ 0.2° and 18.71 ⁇ 0.2° peaks at diffraction angles (2 ⁇ ).
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern (XRPD) of the anhydrous crystal form III of the compound of formula (I) includes positions at 5.85 ⁇ 0.2°, 21.34 ⁇ 0.2°, 14.96 ⁇ 0.2°, and 20.57 ⁇ 0.2°. , 19.78 ⁇ 0.2°, 24.12 ⁇ 0.2°, 18.71 ⁇ 0.2°, 25.13 ⁇ 0.2°, 13.72 ⁇ 0.2°, 24.65 ⁇ 0.2°, 22.76 ⁇ 0.2°, 26.75 ⁇ 0.2°, 14.61 ⁇ 0.2°, 10.81 ⁇ 0.2° and a peak at a diffraction angle (2 ⁇ ) of 16.81 ⁇ 0.2°.
  • the X-ray powder diffraction pattern (XRPD) of the anhydrous crystal form III of the compound of formula (I) includes positions at 5.85 ⁇ 0.2°, 21.34 ⁇ 0.2°, 14.96 ⁇ 0.2°, and 20.57 ⁇ 0.2 °, 19.78 ⁇ 0.2°, 24.12 ⁇ 0.2°, 18.71 ⁇ 0.2°, 25.13 ⁇ 0.2°, 13.72 ⁇ 0.2°, 24.65 ⁇ 0.2°, 22.76 ⁇ 0.2°, 26.75 ⁇ 0.2°, 14.61 ⁇ 0.2°, 10.81 ⁇ 0.2 °, 16.81 ⁇ 0.2°, 21.14 ⁇ 0.2°, 22.54 ⁇ 0.2°, 9.74 ⁇ 0.2°, 21.79 ⁇ 0.2°, 25.74 ⁇ 0.2°, 17.71 ⁇ 0.2°, 19.33 ⁇ 0.2°, 30.36 ⁇ 0.2°, 13.39 ⁇ 0.2 ° and peaks at diffraction angles (2 ⁇ ) of 14.07 ⁇ 0.2°.
  • the crystal form is the hydrate crystal form IV of the compound of formula (I).
  • the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form IV of the compound of formula (I) includes 13.34 ⁇ 0.2°, Peaks at diffraction angles (2 ⁇ ) of 17.41 ⁇ 0.2°, 21.78 ⁇ 0.2°, 20.02 ⁇ 0.2°, 14.85 ⁇ 0.2° and 16.53 ⁇ 0.2°.
  • the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form IV of the compound of formula (I) includes positions at 13.34 ⁇ 0.2°, 17.41 ⁇ 0.2°, 21.78 ⁇ 0.2°, 20.02 ⁇ 0.2°, Peaks at diffraction angles (2 ⁇ ) of 14.85 ⁇ 0.2°, 16.53 ⁇ 0.2°, 19.35 ⁇ 0.2°, 18.64 ⁇ 0.2°, 11.19 ⁇ 0.2°, 5.98 ⁇ 0.2° and 22.67 ⁇ 0.2°.
  • the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form IV of the compound of formula (I) includes positions at 13.34 ⁇ 0.2°, 17.41 ⁇ 0.2°, 21.78 ⁇ 0.2°, 20.02 ⁇ 0.2°, 14.85 ⁇ 0.2°, 16.53 ⁇ 0.2°, 19.35 ⁇ 0.2°, 18.64 ⁇ 0.2°, 11.19 ⁇ 0.2°, 5.98 ⁇ 0.2°, 22.67 ⁇ 0.2°, 20.62 ⁇ 0.2°, 26.72 ⁇ 0.2°, 14.08 ⁇ 0.2°, Peaks at diffraction angles (2 ⁇ ) of 23.82 ⁇ 0.2° and 25.37 ⁇ 0.2°.
  • the crystal form is the hydrate crystal form VIII of the compound of formula (I), and the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form VIII of the compound of formula (I) includes positions at 23.05 ⁇ 0.2°, Peaks at diffraction angles (2 ⁇ ) of 8.73 ⁇ 0.2°, 21.41 ⁇ 0.2°, 15.95 ⁇ 0.2°, 23.50 ⁇ 0.2°, 15.50 ⁇ 0.2° and 25.14 ⁇ 0.2°.
  • the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form VIII of the compound of formula (I) includes positions at 23.05 ⁇ 0.2°, 8.73 ⁇ 0.2°, 21.41 ⁇ 0.2°, 15.95 ⁇ 0.2°, and Peak at diffraction angle (2 ⁇ ) of 19.32 ⁇ 0.2°.
  • the X-ray powder diffraction pattern (XRPD) of the hydrate crystal form VIII of the compound of formula (I) includes locations at 23.05 ⁇ 0.2°, 8.73 ⁇ 0.2°, 21.41 ⁇ 0.2°, 15.95 ⁇ 0.2°, 23.50 ⁇ 0.2°, 15.50 ⁇ 0.2°, 25.14 ⁇ 0.2°, 27.00 ⁇ 0.2°, 31.15 ⁇ 0.2°, 27.70 ⁇ 0.2°, 16.81 ⁇ 0.2°, 19.70 ⁇ 0.2°, 13.22 ⁇ 0.2°, 24.34 ⁇ 0.2°, and Peak at diffraction angle (2 ⁇ ) of 18.59 ⁇ 0.2°.
  • the hydrate of the compound of formula (I) contains 0.5-3.0 water molecules per molecule.
  • the hydrate of the compound of formula (I) contains 0.9-1.8 water molecules per molecule.
  • the crystal form is the compound of formula (I) 2-methyltetrahydrofuran solvate crystal form VI
  • Powder diffraction patterns (XRPD) include diffraction angles (2 ⁇ ) at 22.44 ⁇ 0.2°, 5.63 ⁇ 0.2°, 16.81 ⁇ 0.2°, 20.43 ⁇ 0.2°, 21.57 ⁇ 0.2°, 16.15 ⁇ 0.2° and 22.71 ⁇ 0.2°. peak.
  • the X-ray powder diffraction pattern (XRPD) of the crystal form VI of the 2-methyltetrahydrofuran solvate of the compound of formula (I) includes positions at 22.44 ⁇ 0.2°, 5.63 ⁇ 0.2°, and 16.81 ⁇ 0.2 °, 20.43 ⁇ 0.2°, 21.57 ⁇ 0.2°, 16.15 ⁇ 0.2°, 22.71 ⁇ 0.2°, 6.36 ⁇ 0.2°, 12.60 ⁇ 0.2°, 25.95 ⁇ 0.2°, 24.92 ⁇ 0.2°, 13.69 ⁇ 0.2°, 19.65 ⁇ 0.2 °, 15.13 ⁇ 0.2° and 12.11 ⁇ 0.2° peaks at diffraction angles (2 ⁇ ).
  • the X-ray powder diffraction pattern (XRPD) of the crystal form VI of the 2-methyltetrahydrofuran solvate of the compound of formula (I) includes positions at 22.44 ⁇ 0.2°, 5.63 ⁇ 0.2°, and 16.81 ⁇ 0.2°.
  • each molecule of the 2-methyltetrahydrofuran solvate of the compound of formula (I) contains 0.5-3.0 2-methyltetrahydrofuran molecules.
  • each molecule of the 2-methyltetrahydrofuran solvate of the compound of formula (I) contains 1.0 2-methyltetrahydrofuran molecules.
  • the crystal form is the isopropyl alcohol solvate crystal form V of the compound of formula (I)
  • the X-ray powder diffraction pattern of the isopropyl alcohol solvate crystal form V of the compound of formula (I) is ( XRPD) includes peaks at diffraction angles (2 ⁇ ) of 5.28 ⁇ 0.2°, 10.52 ⁇ 0.2°, 21.29 ⁇ 0.2°, 5.66 ⁇ 0.2°, 13.52 ⁇ 0.2°, 22.44 ⁇ 0.2° and 19.35 ⁇ 0.2°.
  • the X-ray powder diffraction pattern (XRPD) of the isopropanol solvate crystal form V of the compound of formula (I) includes positions at 5.28 ⁇ 0.2°, 10.52 ⁇ 0.2°, 21.29 ⁇ 0.2°, 5.66 ⁇ 0.2°, 13.52 ⁇ 0.2°, 22.44 ⁇ 0.2°, 19.35 ⁇ 0.2°, 18.48 ⁇ 0.2°, 16.77 ⁇ 0.2°, 24.68 ⁇ 0.2°, 19.97 ⁇ 0.2°, 25.67 ⁇ 0.2°, 15.13 ⁇ 0.2°, Peaks at diffraction angles (2 ⁇ ) of 17.82 ⁇ 0.2° and 20.96 ⁇ 0.2°.
  • the X-ray powder diffraction pattern (XRPD) of the isopropanol solvate crystal form V of the compound of formula (I) includes positions at 5.28 ⁇ 0.2°, 10.52 ⁇ 0.2°, 21.29 ⁇ 0.2°, 5.66 ⁇ 0.2°, 13.52 ⁇ 0.2°, 22.44 ⁇ 0.2°, 19.35 ⁇ 0.2°, 18.48 ⁇ 0.2°, 16.77 ⁇ 0.2°, 24.68 ⁇ 0.2°, 19.97 ⁇ 0.2°, 25.67 ⁇ 0.2°, 15.13 ⁇ 0.2°, 17.82 Diffraction of ⁇ 0.2°, 20.96 ⁇ 0.2°, 14.86 ⁇ 0.2°, 12.48 ⁇ 0.2°, 11.94 ⁇ 0.2°, 14.24 ⁇ 0.2°, 23.87 ⁇ 0.2°, 23.25 ⁇ 0.2°, 29.51 ⁇ 0.2° and 27.70 ⁇ 0.2° Peak at angle (2 ⁇ ).
  • each molecule of the isopropyl alcohol solvate of the compound of formula (I) contains 1.0-5.0 isopropyl alcohol molecules.
  • each molecule of the isopropyl alcohol solvate of the compound of formula (I) contains 4.2 isopropyl alcohol molecules.
  • the crystal form is the isopropanol-aqueous solvate crystal form VII of the compound of formula (I), and the X of the isopropyl alcohol-aqueous solvate crystal form VII of the compound of formula (I) - Ray powder diffraction pattern (XRPD) includes diffraction angles (2 ⁇ ) at 23.77 ⁇ 0.2°, 24.36 ⁇ 0.2°, 18.56 ⁇ 0.2°, 5.94 ⁇ 0.2°, 22.59 ⁇ 0.2°, 20.30 ⁇ 0.2° and 17.79 ⁇ 0.2° The peak at.
  • the X-ray powder diffraction pattern (XRPD) of the isopropyl alcohol-aqueous heterosolvate crystal form VII of the compound of formula (I) includes positions at 23.77 ⁇ 0.2°, 24.36 ⁇ 0.2°, and 18.56 ⁇ 0.2°, 5.94 ⁇ 0.2°, 22.59 ⁇ 0.2°, 20.30 ⁇ 0.2°, 17.79 ⁇ 0.2°, 10.33 ⁇ 0.2°, 12.10 ⁇ 0.2°, 22.26 ⁇ 0.2°, 19.48 ⁇ 0.2°, 21.73 ⁇ 0.2°, 5.29 ⁇ Peaks at diffraction angles (2 ⁇ ) of 0.2°, 25.80 ⁇ 0.2° and 16.45 ⁇ 0.2°.
  • the X-ray powder diffraction pattern (XRPD) of the isopropyl alcohol-aqueous heterosolvate crystal form VII of the compound of formula (I) includes positions at 23.77 ⁇ 0.2°, 24.36 ⁇ 0.2°, and 18.56 ⁇ 0.2 °, 5.94 ⁇ 0.2°, 22.59 ⁇ 0.2°, 20.30 ⁇ 0.2°, 17.79 ⁇ 0.2°, 10.33 ⁇ 0.2°, 12.10 ⁇ 0.2°, 22.26 ⁇ 0.2°, 19.48 ⁇ 0.2°, 21.73 ⁇ 0.2°, 5.29 ⁇ 0.2 °, 25.80 ⁇ 0.2°, 16.45 ⁇ 0.2°, 21.94 ⁇ 0.2°, 28.33 ⁇ 0.2°, 25.04 ⁇ 0.2°, 11.89 ⁇ 0.2°, 17.26 ⁇ 0.2°, 28.85 ⁇ 0.2°, 16.79 ⁇ 0.2°, 23.34 ⁇ 0.2 °, 30.31 ⁇ 0.2° and 14.26 ⁇ 0.2° peaks at diffraction angles (2 ⁇ ).
  • each molecule of the isopropyl alcohol-water heterosolvate of the compound of formula (I) contains 0.5-3 isopropyl alcohol molecules and 0.5-3.0 water molecules.
  • each molecule of the isopropanol-water heterosolvate of the compound of formula (I) contains 2.0 isopropanol molecules and 1.5 water molecules.
  • the fourth aspect of the present invention relates to the use of the above-mentioned pharmaceutical composition or crystal form in the preparation of FGFR inhibitors.
  • the fifth aspect of the present invention relates to the use of the above pharmaceutical composition or crystal form in the preparation and treatment of liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or Uses in drugs for rhabdomyosarcoma.
  • the present invention also provides a method for inhibiting FGFR activity, which method includes administering an effective therapeutic amount of the above pharmaceutical composition or crystal form to a patient in need of treatment.
  • the present invention also provides a method for treating liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma, the method comprising Administer an effective therapeutic amount of the above-mentioned pharmaceutical composition or crystal form to a patient in need of treatment.
  • the present invention also provides an above-mentioned pharmaceutical composition or crystal form, which is used as an FGFR inhibitor.
  • the present invention also provides the above pharmaceutical composition or crystal form, which is used to treat liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, and glioblastoma. tumor or rhabdomyosarcoma.
  • Figure 1 is a DSC analysis chart of the compound of formula (I).
  • the abscissa represents temperature (°C), and the ordinate represents heat flow A (w/g).
  • Figure 2 is a DSC analysis chart of glyceryl behenate.
  • the abscissa represents temperature (°C), and the ordinate represents heat flow A (w/g).
  • Figure 3 is the XRPD pattern of the compound of formula (I) after different processing methods.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity. From top to bottom, the compound of formula (I) after wet granulation, unprocessed XRPD patterns of compounds of formula (I) and grinded compounds of formula (I).
  • Figure 4 is the XRPD pattern of granules at different stages of granulation.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity. From top to bottom are the compounds of formula (I) in the final mixture and the formula after fluidized bed drying. XRPD patterns of compound (I), wet granulated compound of formula (I), and untreated compound of formula (I).
  • Figure 5 is a comparison of the dissolution curves of the original prescription and the tablets obtained in Experiment 13 and Experiment 17.
  • the abscissa is time (min), and the ordinate is dissolution percentage (%). From top to bottom, the original prescription, Experiment 17, Experiment 13 dissolution curve.
  • Figure 6 is a comparison chart of the dissolution curves of the tablets obtained from the original prescription and experiments 18-20.
  • the abscissa is time (min), and the ordinate is dissolution percentage (%). From top to bottom, it is the original prescription, experiment 18, and experiment 20.
  • Figure 7 is an XRPD diffraction spectrum of Form I.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity.
  • Figure 8 is a DSC chart of crystal form I.
  • the abscissa represents temperature (°C), and the ordinate represents heat flow A (w/g).
  • Figure 9 is a TGA diagram of Form I.
  • the abscissa represents temperature (° C.) and the ordinate represents weight change (%).
  • Figure 10 is a 1 H-NMR chart of Form I, and the abscissa indicates chemical shift (ppm).
  • Figure 11 is the XRPD diffraction spectrum of Form II.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity.
  • Figure 12 is a DSC chart of crystal form II.
  • the abscissa represents temperature (°C) and the ordinate represents heat flow A (w/g).
  • Figure 13 is a TGA diagram of crystal form II.
  • the abscissa represents temperature (°C) and the ordinate represents weight change (%).
  • Figure 14 is a 1 H-NMR chart of the crystal form II, and the abscissa represents the chemical shift (ppm).
  • Figure 15 is the XRPD diffraction spectrum of Form III.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity.
  • Figure 16 is a DSC chart of crystal form III.
  • the abscissa represents temperature (°C) and the ordinate represents heat flow A (w/g).
  • Figure 17 is a TGA diagram of Form III.
  • the abscissa represents temperature (°C) and the ordinate represents weight change (%).
  • Figure 18 is a 1 H-NMR chart of Form III, and the abscissa represents the chemical shift (ppm).
  • Figure 19 is the XRPD diffraction spectrum of Form IV.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity.
  • Figure 20 is a DSC chart of crystal form IV.
  • the abscissa represents temperature (°C), and the ordinate represents heat flow A (w/g).
  • Figure 21 is a TGA diagram of Form IV.
  • the abscissa represents temperature (° C.), and the ordinate represents weight change (%).
  • Figure 22 is a 1 H-NMR chart of Form IV, and the abscissa indicates chemical shift (ppm).
  • Figure 23 is the XRPD diffraction spectrum of crystal form V.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity.
  • Figure 24 is a DSC chart of crystal form V.
  • the abscissa represents temperature (°C), and the ordinate represents heat flow A (w/g).
  • Figure 25 is a TGA diagram of crystal form V.
  • the abscissa represents temperature (° C.), and the ordinate represents weight change (%).
  • Figure 26 is a 1 H-NMR chart of Form V, and the abscissa indicates chemical shift (ppm).
  • Figure 27 is the XRPD diffraction spectrum of Form VI.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity.
  • Figure 28 is a DSC chart of Form VI.
  • the abscissa represents temperature (°C), and the ordinate represents heat flow A (w/g).
  • Figure 29 is a TGA diagram of Form VI.
  • the abscissa represents temperature (° C.), and the ordinate represents weight change (%).
  • Figure 30 is a 1 H-NMR chart of Form VI.
  • the abscissa represents the chemical shift (ppm).
  • Figure 31 is the XRPD diffraction spectrum of crystal form VII.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity.
  • Figure 32 is a DSC chart of crystal form VII.
  • the abscissa represents temperature (°C), and the ordinate represents heat flow A (w/g).
  • Figure 33 is a TGA diagram of crystal form VII.
  • the abscissa represents temperature (° C.), and the ordinate represents weight change (%).
  • Figure 34 is a 1 H-NMR chart of Form VII.
  • the abscissa represents the chemical shift (ppm).
  • Figure 35 is the XRPD diffraction spectrum of Form VIII.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity.
  • Figure 36 is a DSC chart of crystal form VIII.
  • the abscissa represents temperature (°C), and the ordinate represents heat flow A (w/g).
  • Figure 37 is a TGA diagram of crystal form VIII.
  • the abscissa represents temperature (° C.), and the ordinate represents weight change (%).
  • Figure 38 is a 1 H-NMR chart of Form VIII, and the abscissa represents chemical shift (ppm).
  • Figure 39 is an electron microscope scanning image of Form I.
  • Figure 40 is the XRPD pattern after the volume stability experiment of crystal form I.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity. From top to bottom in the figure are the anhydrate of the compound of formula (I). I was placed in an open container at 25°C/92%RH, an open container at 40°C/75%RH, and a closed container at 60°C for 1 week, and the crystal form I was subjected to 120°C under visible light at 25°C.
  • Figure 41 is the water adsorption isotherm of crystalline form I.
  • the abscissa is the water activity P/PO, and the ordinate is the mass scale change (%). From top to bottom in the figure are desorption in cycle 1, adsorption in cycle 1, and desorption in cycle 2. , cycle 2 adsorption curve.
  • Figure 42 is a water activity change curve and a mass change curve of Form I, in which the abscissa is time (minutes), the ordinate on the left is mass change (%), and the ordinate on the right is water activity (P/PO), From top to bottom in the figure are the water activity change curve and mass change curve of Form I.
  • Figure 43 shows the XRPD pattern of Form I before and after DSV testing.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity.
  • Figure 44 is the XRPD diagram of crystal form I before and after the compression simulation test.
  • the abscissa represents the 2 ⁇ value (degrees), and the ordinate represents the peak intensity. From top to bottom in the figure are the starting crystal form I, the hydraulic press and the XRPD patterns of Form I after compression at 2MPa, 5MPa and 10MPa.
  • Figure 45 is the XRPD pattern of Form I before and after the wet granulation simulation experiment test.
  • the abscissa indicates the 2 ⁇ value (degrees), and the ordinate indicates the peak intensity. From top to bottom in the figure, it is made with isopropyl alcohol and water.
  • “Pharmaceutical composition” means a mixture containing one or more compounds described herein, or physiologically/pharmaceutically acceptable crystalline forms, salt forms or prodrugs thereof, and other chemical components, as well as other components such as physiologically/pharmaceutically acceptable Medicinal carrier.
  • the purpose of pharmaceutical compositions is to facilitate administration to living organisms and facilitate the absorption of active ingredients to exert biological activity.
  • the pharmaceutical composition of the present invention may include one or more pharmaceutically acceptable carriers, which include but are not limited to: binders, lubricants, diluents, stabilizers, buffers, adjuvants, carriers, emulsifiers, Viscosity regulators, surfactants, preservatives, flavoring or coloring agents.
  • pharmaceutically acceptable carriers include but are not limited to: binders, lubricants, diluents, stabilizers, buffers, adjuvants, carriers, emulsifiers, Viscosity regulators, surfactants, preservatives, flavoring or coloring agents.
  • binder refers to a pharmaceutically acceptable compound or composition added to a formulation to hold active pharmaceutical ingredients and inactive ingredients together in a cohesive mixture. Dry binders used for direct compaction must exhibit cohesion and adhesion so that the particles coalesce when compacted.
  • the binders used in wet granulation are hydrophilic and soluble in water, and usually dissolve in water to form a wet mass which is then granulated.
  • Suitable binders include (but are not limited to) providone, Plasdone K29/32, Plasdone S-630, hydroxypropyl cellulose, methyl cellulose, polyvinylpyrrolidone, aluminum stearate, hydroxypropyl Methylcellulose and its analogs. It is possible that these binders additionally act as water sequestrants (e.g. providone).
  • blowing agent refers to any pharmaceutically acceptable substance that evolves gas in response to an irritant (eg, carbon dioxide upon acidification).
  • irritant eg, carbon dioxide upon acidification
  • blowing agents are carbonates, for example metal carbonates (such as sodium carbonate, potassium carbonate, magnesium carbonate, calcium carbonate or aluminum carbonate) or organic carbonates (such as sodium diglycinate carbonate, dimethyl carbonate acid salt or ethylene carbonate).
  • metal carbonates such as sodium carbonate, potassium carbonate, magnesium carbonate, calcium carbonate or aluminum carbonate
  • organic carbonates such as sodium diglycinate carbonate, dimethyl carbonate acid salt or ethylene carbonate
  • a blowing agent is a bicarbonate, for example a metal bicarbonate (such as sodium bicarbonate or potassium bicarbonate).
  • filler refers to any pharmaceutically acceptable substance or composition added to a formulation to increase volume. Suitable fillers include, but are not limited to, mannitol, lactose, microcrystalline cellulose, silicified microcrystalline cellulose, and dicalcium phosphate.
  • lubricant refers to any pharmaceutically acceptable agent that reduces surface friction, lubricates the particle surface, reduces the tendency of static electricity to accumulate, and/or reduces the brittleness of the particle. Therefore, lubricants act as anti-aggregation agents.
  • Conventional lubricants include stearic acid and related compounds such as magnesium stearate and sodium stearyl fumarate.
  • Alternative lubricants include glycerol dibehenate, colloidal silica, talc, other hydrogenated vegetable oils, or triglycerides. Examples of suitable alternative lubricants include, but are not limited to, glyceryl dibehenate.
  • disintegrant refers to a substance added to a composition to help it break apart (disintegrate) and release the pharmaceutical agent.
  • examples of disintegrants include, but are not limited to, non-sugar water-soluble polymers such as cross-linked polyvinylpyrrolidone.
  • Other disintegrants that may also be used include, for example, croscarmellose sodium, sodium starch glycolate and the like, see for example Khattab (1992) J. Pharm. Pharmacol. 45:687-691.
  • hydroxypropyl cellulose is a partially substituted poly(hydroxypropyl) ether of cellulose.
  • Commercially available hydroxypropylcellulose is divided into many specifications according to different molecular weights, and its aqueous solutions also have different viscosities.
  • hydroxypropyl cellulose LF refers to hydroxypropyl cellulose with an average molecular weight of about 95,000, or hydroxypropyl cellulose with LF specifications.
  • “Hydroxypropyl cellulose JF” refers to hydroxypropyl cellulose with an average molecular weight of about 140,000, or JF grade hydroxypropyl cellulose.
  • Hydropropyl cellulose EXF or EF refers to hydroxypropyl cellulose with an average molecular weight of about 80,000, or hydroxypropyl cellulose with EXF or EF grade specifications.
  • Silicified microcrystalline fiber is Silicified microcrystalline cellulose, which refers to the preparation of microcrystalline cellulose and colloidal silica by blending and drying in water. Calculated as a dry product, it generally contains 94.0 to 100% microcrystalline cellulose. .
  • tablette refers to the process of applying compressive force (eg in a mold) to a formulation (powder or granules) to form tablets.
  • tablette means any tablet formed by such a process.
  • tablette is used in its common context and refers to a solid composition made by compressing and/or molding a mixture of the compositions into a form convenient for swallowing or application to any body cavity.
  • punch sticking refers to the adhesion of material to the surface of the tablet punch. If sufficient material is built up on the punch surface, the tablet weight may fall below acceptable limits, among other defects. (Journal of Pharmaceutical Sciences, Vol. 93(2), 2004).
  • Polymorph refers to a crystalline form that has the same chemical composition but different spatial arrangements of the molecules, atoms, and/or ions that make up the crystal. Although polymorphs have the same chemical composition, they differ in packing and geometric arrangement and may exhibit different physical properties such as melting point, shape, color, density, hardness, deformability, stability, solubility, dissolution velocity and similar properties. Depending on their temperature-stability relationship, two polymorphs can be monotropic or tautotropic. For a unidenaturing system, the relative stability between the two solid phases remains unchanged when the temperature changes. In contrast, in tautotropic systems, there is a transition temperature at which the stability of the two phases switches. The phenomenon of a compound existing in different crystal structures is called drug polymorphism.
  • the various crystalline structures of the present invention can be distinguished from each other using various analytical techniques known to those of ordinary skill in the art. Such techniques include, but are not limited to, X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and/or thermogravimetric analysis (TGA).
  • XRPD X-ray powder diffraction
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • X-ray powder diffraction patterns can be obtained with measurement errors that depend on the measurement conditions used.
  • the intensity in an X-ray powder diffraction pattern may fluctuate depending on the conditions of the material used. Relative strengths may also vary with experimental conditions, and accordingly, the exact strengths should not be taken into account.
  • the measurement error of conventional powder X-ray powder diffraction angles is usually about 5% or less, and this degree of measurement error should be regarded as belonging to the above-mentioned diffraction angles. Accordingly, the crystal structures of the present invention are not limited to crystal structures that provide an X-ray powder diffraction pattern that is identical to the X-ray powder diffraction pattern depicted in the figures disclosed herein.
  • any crystal structure having an X-ray powder diffraction pattern substantially identical to those disclosed in the drawings falls within the scope of the present invention.
  • Those skilled in the art should have the ability to determine that X-ray powder diffraction patterns are substantially the same.
  • Other suitable standard calibrations are known to those skilled in the art.
  • the relative strength may vary with crystal size and shape.
  • Crystalline forms of the compounds of the invention are characterized by their X-ray powder diffraction patterns. Therefore, using Cu K ⁇ radiation with The X-ray powder diffraction pattern of the salt was collected on a Bruker D8 Discover X-ray powder diffractometer operated in reflection mode with a GADDS (General Area Diffraction Detector System) CS. The tube voltage and current were set to 40kV and 40mA for acquisition scan respectively. Scan the sample over a 2 ⁇ range of 3.0° to 40° for a period of 60 seconds. The diffractometer was calibrated using corundum standards for peak positions expressed in 2 ⁇ . All analyzes were performed at typically 20°C-30°C. Data were acquired and integrated using GADDS for WNT software version 4.1.14T. Diffractograms were analyzed using DiffracPlus software with version 9.0.0.2 of Eva released in 2003.
  • GADDS General Area Diffraction Detector System
  • Measurement differences associated with the results of such X-ray powder diffraction analysis arise from a variety of factors including: (a) errors in sample preparation (e.g., sample height), (b) instrument errors, (c) calibration differences, ( d) operator errors (including those occurring in determining peak positions), and (e) properties of the material (eg preferred orientation errors). Calibration errors and sample height errors often cause all peaks to be shifted in the same direction. Generally speaking, this calibration factor will bring the measured peak position consistent with the expected peak position and within ⁇ 0.2° of the expected 2 ⁇ value.
  • DSC Differential scanning calorimetry
  • Thermogravimetric analysis (TGA) experiments were performed in a TA Instruments TM model Q500. Samples (approximately 10-30 mg) were placed in pre-tare platinum pans. Accurately measure the sample weight by instrument and record to the nearest thousandth of a mg. The furnace was purged with nitrogen at 100 ml/minute. Data were collected between room temperature and 300°C at a heating rate of 10°C/minute.
  • the experimental method of using the dynamic moisture adsorption method (DVS) to characterize the acid salt of the compound of crystalline form (I) is to take a small amount of the acid salt powder of the compound of crystalline form (I) and place it in a precision sample tray matched with the instrument. After loading the sample , sent to the instrument for testing. All instruments used in the dynamic moisture adsorption method in this patent are DVS Intrinsic.
  • the reagents in the embodiments of the present invention are known and can be purchased on the market.
  • the reagents used are commercially available industrial grade or analytical grade reagents, or can be synthesized using or according to methods known in the art.
  • the formula ( I) Compound API raw materials are prepared according to patent WO2008075068A1.
  • magnesium carbonate, microcrystalline cellulose, mannitol, and hydroxypropyl fiber were added according to the components and contents recorded in Table 1 below.
  • Vegetable EXF, carboxymethyl starch sodium and the compound of formula (I) are sieved and premixed, then poured into a wet granulation pot, purified water is added to the powder, and a wet granulator is used for granulation. After wet granulation, use a fluidized bed dryer to dry to appropriate moisture ( ⁇ 2% w/w). After the dried granules are dried and granulated, glyceryl behenate is then added to the granules and mixed evenly to obtain final mixed granules, which are then compressed into tablets, resulting in sticking.
  • NA means that it does not contain this component, and the following experiments have the same meaning.
  • the API used in the original prescription was prepared according to WO2008075068A2, and the API used in Experiments 1-4 was the anhydrous crystal form I of the compound of formula (I).
  • the API compound of formula (I) used in Example 6 which was prepared according to patent WO2008075068A1, other examples are not specifically specified.
  • the APIs used in the experimental research are all anhydrous crystal form I of the compound of formula (I). .
  • the experimental results are shown in Figures 1 to 4.
  • the DSC and XRPD measurement results of the samples show that the melting point of the compound of formula (I) is 172.38°C, has no Tg value, and does not absorb moisture under the conditions of 25°C and 80% RH.
  • the melting point of glyceryl behenate is: 71.63°C and has no Tg value. It is preliminarily determined that the XRPD of the compound of formula (I) after moist heat treatment and grinding shows no crystalline change.
  • microcrystalline cellulose and mannitol in the original prescription were added internally and externally (1/2 was used for wet granulation and 1/2 was used for external mixing) to dilute the ungranulated compound of formula (I).
  • the results show that : The prepared granules will stick to each other within 3 minutes of tableting.
  • the tableting conditions of comparative experiments 11 and 15 show that when the amount of binder is reduced (the proportion of hydroxypropylcellulose LF is reduced from 7% to 5%, and the concentration is reduced from 12% to 10%), the fluidized bed is used at the same time. When drying, even if the dosage of glyceryl behenate is increased to 5%, sticking will still occur.
  • Experiments 13 and 17 used a higher viscosity adhesive (hydroxypropyl cellulose LF), added the lubricant magnesium stearate, and increased the dosage of glyceryl behenate to solve the sticking problem. .
  • the properties of the final mixed particles were changed, so the tablet dissolution efficiency of the coated tablets prepared in Experiment 13 and Experiment 17 was evaluated.
  • the solubility was measured in a pH 6.8 phosphate buffer solution at 37°C ⁇ 0.5°C using a paddle method with a stirring speed of 50 rpm.
  • the dissolution medium was withdrawn and the concentration in the solution was determined by UV broad spectrum method at 311 nm wavelength against an external standard solution.
  • the experimental data are detailed in Table 5, and the dissolution curve comparison is shown in Figure 5.
  • Solubility was measured in pH 6.8 phosphate buffer solution using a paddle method with a stirring speed of 50 rpm. At 15, 30, and 60 minutes, the dissolution medium was withdrawn and the concentration of the solution was determined by UV broad spectrum method at 311 nm wavelength against an external standard solution. The experimental data are detailed in Table 7, and the dissolution curve is shown in Figure 6.
  • Experiment 18 examined the improvement of dissolution release by the amount of filler. The results showed that after the proportion of microcrystalline cellulose increased from 9.685% to 30.182%, the dissolution release of the tablets in Experiment 17 at 30 minutes improved to a certain extent. This may be due to the microcrystalline cellulose. When the amount of cellulose is greater than 30%, the disintegration ability is enhanced. However, it can still be observed that the tablet disintegrates slowly during the dissolution process, and larger lumps can be observed to accumulate at the bottom of the cup at 20 minutes.
  • Experiment 19 examined the improvement of dissolution release by adjusting filler dosage, disintegrant dosage, and adding method. The results showed that based on Experiment 17, the disintegrant proportion was increased (7.5% to 10%) and the dosage was increased to 5. After % internal addition and 5% external addition, the dissolution difference was larger. Some tablets had less accumulation at the bottom of the cup. At this time, the dissolution and release degree was higher, reaching 90% in 30 minutes. However, some tablets have larger pieces accumulated at the bottom of the cup, resulting in reduced dissolution. Only 73% is released in 30 minutes. When accelerated to 250 rpm, the lumps can be seen to quickly disintegrate.
  • Experiment 20 considers the insoluble particles that appear during the dissolution process. Based on Experiment 18, the proportion of water-soluble mannitol is increased and the proportion of microcrystalline cellulose is reduced (microcrystalline cellulose is 20% and mannitol is 20.63%). At the same time, after reducing the amount of lubricant (glyceryl behenate was reduced from 5% to 3%, and magnesium stearate was reduced from 3% to 1.5%), the results showed that although there were still small agglomerates during the dissolution process , but the dissolution release is the best.
  • lubricant glyceryl behenate was reduced from 5% to 3%, and magnesium stearate was reduced from 3% to 1.5%
  • Fluidized bed drying transfer the wet particles to a 3L fluidized bed for drying. When the moisture content of the particles is ⁇ 2%, drying is stopped. The final moisture content of the pellets was 1.4%.
  • Dry granulation Use Comil U5 for wet granulation, with a screen aperture of 1575 ⁇ m and a rotation speed of 2500 rpm. Since a certain amount of larger particles remain on the screen and cannot pass through the screen, the rotation speed is increased to 2700 rpm. The granules after dry granulation have a larger amount of fine powder.
  • Adding disintegrant and lubrication Calculate the proportion of external excipients based on the quality of the dried particles.
  • the additional auxiliary materials are weighed and sieved and then mixed according to the set parameters.
  • the mixing times for adding croscarmellose sodium, glyceryl behenate, and magnesium stearate are 8 minutes, 30 minutes, and 3 minutes respectively.
  • BU sampling and powder central control Use a sampler to sample the final mixed particles to measure BU, and at the same time detect the powder bulk density, tap density, and particle size distribution.
  • the experimental results are shown in Table 9. The BU result measurement showed that it was qualified (mean value: 100.9%), and there was no excess.
  • the target tablet weight of 20mg specification is 96.81mg, the single tablet limit is 92.5%-107.5%, and the tablet weight range is 89.55-104.07mg.
  • the 20mg specification uses two sets of 6mm non-chrome plated punches at 30rpm for tableting. Due to the large amount of fine powder, the main pressure fluctuates greatly during the tableting process, but the tablet weight is relatively stable.
  • the tableting process of 20mg specification lasted for 90 minutes, and the appearance of the tablets was smooth and smooth, with no sticking phenomenon during the process. However, due to the large amount of fine powder, powder leakage occurred during the tableting process, and the yield was reduced.
  • the final tablet was 442.74g (about 4500EA).
  • Coating Coat the pressed tablets, and the solid content of the coating liquid is 18%.
  • the target weight gain is 3%, and the weight gain range is 2.% to 3.4%.
  • the final weight gain of the 20mg specification was 3.3%, and the final yield was 453.4g.
  • the surface of the coated tablet was smooth and there was no color difference.
  • Bottled Packed at 24EA/bottle, each bottle contains one bag of 1g desiccant.
  • the equipment is debugged according to the set parameters for bottling, and finally the bottled samples are sent to analysis and testing for sampling.
  • Fluidized bed drying Transfer the combined wet particles to a 6L fluidized bed for drying. When the moisture content of the particles is ⁇ 2%, drying is stopped. The final moisture content of the pellets was 0.94%.
  • Dry granulation Use Comil U5 to wet granulate the granules, the screen aperture is 1575 ⁇ m, and the rotation speed is 2250rpm. The granules after dry granulation have a larger amount of fine powder.
  • Adding disintegrant and lubrication Calculate the proportion of external excipients based on the quality of the dried particles.
  • the additional auxiliary materials are weighed and sieved and then mixed according to the set parameters.
  • the mixing times for adding croscarmellose sodium, glyceryl behenate, and magnesium stearate are 8 minutes, 30 minutes, and 3 minutes respectively.
  • BU sampling and powder central control Use a sampler to sample the final mixed particles to measure BU, and at the same time detect the powder bulk density, tap density, and particle size distribution.
  • the experimental results are shown in Table 9. The BU result measurement showed that it was qualified (mean value: 101.7%), and no single value exceeded the limit.
  • Tablet compression The target tablet weight of 80mg specification is 387.22mg, the single tablet limit is 95%-105%, and the tablet weight range is 367.86-406.58mg.
  • the target tablet weight of 80mg specification is 387.22mg, the single tablet limit is 95%-105%, and the tablet weight range is 367.86-406.58mg.
  • When pressing use 2 sets of 6mm and 11mm non-chrome plated punches and press at 30rpm. During the tableting process, the main pressure is relatively stable and powder leakage is significantly improved.
  • the compression of 80 mg tablets lasted for 60 minutes. The appearance of the tablets was smooth and smooth, and there was no sticking phenomenon during the process.
  • the final film was 1404.9g (about 3600EA).
  • Coating Coat the pressed tablets, and the solid content of the coating liquid is 18%.
  • the target weight gain is 3%, and the weight gain range is 2.% to 3.4%.
  • the final weight gain of the 80mg specification is 2.84%, and the final yield is 1433.0g.
  • the coated tablet has a smooth surface and no color difference.
  • Bottled Packed at 24EA/bottle, each bottle contains one bag of 1g desiccant.
  • the equipment is debugged according to the set parameters for bottling, and finally the bottled samples are sent to analysis and testing for sampling.
  • Test results The test results all meet the release requirements.
  • the XRPD diffraction patterns of the anhydrate (form I) crystals of the compound of formula (I) obtained by the above preparation methods are the same as shown in Figure 7, and the DSC, TGA, and 1 H-NMR analysis patterns are shown in Figures 8-10.
  • DSC shows a melting point (Tonset) of 171.6°C and an enthalpy of approximately 87 J/g.
  • TGA showed about 0.2% weight loss at about 150°C.
  • 1 H-NMR showed no residual solvent detected.
  • KF indicates that it contains approximately 0.1% water by weight.
  • the SEM image is shown in Figure 39, and its sub-grain size is ⁇ 10 ⁇ m.
  • Form I crystals were placed in an open container at 25°C/92%RH, an open container at 40°C/75%RH, and a closed container at 60°C for 1 week. A stress of 1.2 million lux-hrs was applied to the crystal under visible light at 25°C.
  • the experimental report is shown in the table above, and the DVS analysis chart is shown in Figures 40-43.
  • the results show that the crystalline form I does not absorb moisture when it is lower than 80% RH, and is slightly hygroscopic when it is higher than 80% RH. At 25°C, it absorbs ⁇ 0.1% water from 40% relative humidity to 80% relative humidity, and about 0.4% water from 80% relative humidity to 95% relative humidity. After the DVS test, the sample obtained was still Form I.
  • Form I Approximately 10 mg of Form I crystals were pressed with a hydraulic press at 2 MPa, 5 MPa and 10 MPa, and potential morphological changes and crystallinity were evaluated by XRPD. The experimental results are shown in Figure 44. After compression, Form I showed no morphological changes, but its crystallinity decreased slightly with increasing pressure.
  • the XRPD diffraction patterns of the anhydrous crystal form (form II) of the compound of formula (I) obtained by the above preparation methods are the same, as shown in Figure 11, and the DSC, TGA, and 1 H-NMR analysis patterns are shown in Figures 12-14.
  • DSC shows an endothermic peak at T onset of 155.5°C, with an enthalpy of approximately 6J/g, a melting point (T onset ) of 171.3°C, and an enthalpy of approximately 87J/g.
  • TGA showed about 1.4% weight loss at about 155°C and about 0.2% weight loss from about 155°C to 170°C.
  • 1 H-NMR showed 0.2% by weight of ethyl acetate remaining.
  • KF indicates that it contains approximately 0.4% water by weight.
  • the XRPD diffraction patterns of the crystalline form (form IV) of the hydrate of the compound of formula (I) obtained by the above preparation methods are the same as shown in Figure 19, and the DSC, TGA, and 1 H-NMR analysis patterns are shown in Figures 20-22.
  • DSC shows a dehydration peak at a T onset of 41.8°C with an enthalpy of approximately 23 J/g, an endothermic peak with an enthalpy of approximately 30 J/g at a T onset of 116.5°C, and an exothermic peak at a T onset of 127.4°C.
  • the enthalpy is about 51J/g.
  • TGA melts at a T onset of 171.0°C with an enthalpy of approximately 69 J/g.
  • TGA showed a weight loss of approximately 2.8% at approximately 170°C.
  • KF shows it contains about 6.4% water by weight, equivalent to 1.8 water molecules.
  • the XRPD diffraction patterns of the crystalline form (form VI) of the 2-methyltetrahydrofuran solvate of the compound of formula (I) obtained by the above preparation methods are the same, as shown in Figure 27, and the DSC, TGA, and 1 H-NMR analysis patterns are as shown in Figure 28 -30 shown.
  • DSC shows a desolvation peak at Tonset of 97.3°C with an enthalpy of approximately 62 J/g, and an exothermic peak at Tonset of 117.9°C with an enthalpy of approximately 41 J/g. It then melts at Tonset of 170.5°C with an enthalpy of about 61 J/g.
  • TGA showed approximately 9.9% weight loss at approximately 150°C.
  • 1 H-NMR showed 15.7% by weight of 2-methyltetrahydrofuran remaining, equivalent to 1.0 molecules of 2-methyltetrahydrofuran.
  • the XRPD diffraction patterns of the isopropanol/water solvate crystal form (form VII) of the compound of formula (I) obtained by the above preparation methods are the same, as shown in Figure 31, and the DSC, TGA, and 1 H-NMR analysis patterns are as shown in Figure 32 -34 shown.
  • DSC shows a desolvation peak at a Tonset of 37.8°C with an enthalpy of approximately 59 J/g, an endothermic peak at a Tonset of 88.1°C with an enthalpy of approximately 95 J/g, and a desolvation peak at a Tonset of 114.1°C.
  • Thermal peak, enthalpy is about 36J/g.
  • the weight loss is about 3.6% from about 65°C to 100°C, and the weight loss is about 2.2% from about 100°C to 130°C.
  • 1 H-NMR showed 20.1% by weight of isopropanol remaining, equivalent to 2.0 molecules of isopropanol.
  • KF indicates that it contains approximately 4.3% water, equivalent to 1.5 water molecules.
  • Solvent activity experiments were performed in an isopropanol/water system at 25°C to determine the critical water activity between the free forms Form I, Form II, Form VII and Form VIII.
  • Crystal form VII is a thermodynamic product, corresponding to the isopropyl alcohol/water (v/v) from 98/2 to 50/50; and at 25°C, when a.w. is between 0.66 and 0.96 and isopropanol activity is between 0.73 and 0.52,
  • Form VII is a thermodynamic product corresponding to isopropanol/water ( v/v) from 90/10 to 50/50.
  • Form I is the thermodynamic product.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique et une substance polymorphe d'un inhibiteur de FGFR, et leur utilisation pharmaceutique. L'inhibiteur de FGFR est un inhibiteur du récepteur du facteur de croissance des fibroblastes avec une structure de formule (I). En adoptant un adhésif approprié et un support pharmaceutiquement acceptable, une préparation pharmaceutique appropriée pour une production industrielle a été développée. Un polymorphe d'un composé représenté par la formule (I) a été en outre développé. Selon les solutions techniques, une préparation pharmaceutique répondant aux exigences de recherche clinique et d'entrée de marché de médicament peut être développée, et le problème d'accessibilité de médicament peut être résolu.
PCT/CN2022/110810 2022-08-08 2022-08-08 Composition pharmaceutique et substance polymorphe d'inhibiteur de fgfr, et leur utilisation pharmaceutique WO2024031226A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/110810 WO2024031226A1 (fr) 2022-08-08 2022-08-08 Composition pharmaceutique et substance polymorphe d'inhibiteur de fgfr, et leur utilisation pharmaceutique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/110810 WO2024031226A1 (fr) 2022-08-08 2022-08-08 Composition pharmaceutique et substance polymorphe d'inhibiteur de fgfr, et leur utilisation pharmaceutique

Publications (1)

Publication Number Publication Date
WO2024031226A1 true WO2024031226A1 (fr) 2024-02-15

Family

ID=89850133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/110810 WO2024031226A1 (fr) 2022-08-08 2022-08-08 Composition pharmaceutique et substance polymorphe d'inhibiteur de fgfr, et leur utilisation pharmaceutique

Country Status (1)

Country Link
WO (1) WO2024031226A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075068A2 (fr) * 2006-12-21 2008-06-26 Astrazeneca Ab Nouveaux composés
CN102170885A (zh) * 2008-09-30 2011-08-31 安斯泰来制药株式会社 口服用药物组合物
CN104853750A (zh) * 2012-12-21 2015-08-19 阿斯利康(瑞典)有限公司 N-[5-[2-(3,5-二甲氧基苯基)乙基]-2h-吡唑-3-基]-4-[(3r,5s)-3,5-二甲基哌嗪-1-基]苯甲酰胺的医药配制品

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075068A2 (fr) * 2006-12-21 2008-06-26 Astrazeneca Ab Nouveaux composés
CN102170885A (zh) * 2008-09-30 2011-08-31 安斯泰来制药株式会社 口服用药物组合物
CN104853750A (zh) * 2012-12-21 2015-08-19 阿斯利康(瑞典)有限公司 N-[5-[2-(3,5-二甲氧基苯基)乙基]-2h-吡唑-3-基]-4-[(3r,5s)-3,5-二甲基哌嗪-1-基]苯甲酰胺的医药配制品

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAVINE, PAUL R. ET AL.: "AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family", CANCER RESEARCH, vol. 72, no. 8, 15 April 2012 (2012-04-15), XP055065340, DOI: 10.1158/0008-5472.CAN-11-3034 *
HUAXING LUO, FAN YA: "Progress in Pharmaceutical Sciences", PROGRESS IN PHARMACEUTICAL SCIENCES, vol. 33, no. 6, 25 June 2009 (2009-06-25), pages 279, XP093137287 *

Similar Documents

Publication Publication Date Title
US11123338B2 (en) C-met modulator pharmaceutical compositions
TWI833686B (zh) Lsd1 抑制劑之調配物
CN111432803A (zh) 包含血浆激肽释放酶抑制剂的剂型
WO2018108101A1 (fr) Nouvelles formes cristallines d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl]amino} acétique et leur procédé de préparation
JP2019214605A (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
JP7437460B2 (ja) Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
US10583087B2 (en) Pharmaceutical composition for oral administration
WO2024031226A1 (fr) Composition pharmaceutique et substance polymorphe d'inhibiteur de fgfr, et leur utilisation pharmaceutique
WO2018233437A1 (fr) Forme cristalline de baricitinib et procédé de préparation correspondant
WO2019205812A1 (fr) Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
TW201840320A (zh) 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物
CN106994121A (zh) 一种用于治疗癌症的药物组合物
WO2023198055A1 (fr) Polymorphe de 7,8-dihydroxyflavone et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22954206

Country of ref document: EP

Kind code of ref document: A1